Sunday 18 October 2026
Export FULC’s income statement to Excel — free account
Fulcrum Therapeutics, Inc.
FULC Healthcare Biotechnology
Fulcrum Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $80.0 million, up 2,752.0% from fiscal 2023. In the quarter to June 2026, EPS fell 21.4% and free cash flow fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.65
0.02
−0.54%
Follow FULC
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 5 | 4 | 3 | — | — | — | — | — |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
P/S ratio |
— | 3.53 | 157.59 | 56.04 | 32.64 | 33.65 | — | — | — |
Altman Z-Score |
— | 8.22 | 7.92 | 3.94 | 14.20 | 1.89 | — | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | 13.38 | 7.46 | 3.78 | 8.73 | (1.69) | — | — | — |
Beneish M-Score |
— | 21.24 | 0.62 | (1.86) | (1.74) | — | — | — | — |
P/Operating CF |
— | (17.38) | (19.09) | (18.05) | (28.62) | (14.97) | — | — | — |
P/B ratio |
— | 1.20 | 1.88 | 1.79 | 2.96 | 3.12 | — | — | — |
Price to Tangible BV |
— | 1.20 | 1.88 | 1.79 | 2.96 | 3.12 | — | — | — |
EV/Sales |
— | 0.61 | 73.38 | 24.05 | 21.26 | 20.85 | — | — | — |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
— | (22.68) | (2.26) | (1.57) | (5.19) | (3.43) | — | — | — |
EV/FCF |
— | (20.15) | (2.25) | (1.54) | (5.08) | (3.35) | — | — | — |
Quick Ratio |
27.00 | 22.01 | 17.31 | 12.15 | 11.55 | 4.32 | 7.98 | 17.33 | 0.16 |
Current Ratio |
27.40 | 22.63 | 17.71 | 12.41 | 11.77 | 4.47 | 8.24 | 17.52 | 0.48 |
Net Debt/EBITDA |
4.23 | 11.87 | 2.18 | 1.84 | 2.78 | 1.63 | 1.18 | 2.26 | 0.02 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.31 | 0.01 | 0.03 | 0.11 | 0.07 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.80 | 0.23 | 0.93 | 0.88 | 0.97 | 0.76 | 0.44 | 0.58 | 0.79 |
Capex/Depreciation |
(0.23) | (0.17) | (0.23) | (0.81) | (0.68) | (0.56) | (0.42) | (6.68) | (2.67) |
| (25.30%) | (4.07%) | (44.84%) | (53.53%) | (52.72%) | (77.68%) | (764.85%) | 80.77% | 52.35% | |
| (23.89%) | (3.75%) | (40.19%) | (47.60%) | (44.35%) | (59.01%) | (91.54%) | (86.89%) | (56.31%) | |
ROIC |
0.00% | (679.86%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (653.65%) | (1,570.56%) |
Return on Tangible Assets |
(21.56%) | (4.01%) | (41.64%) | (55.57%) | (37.75%) | (69.99%) | (92.44%) | (48.68%) | (1,697.06%) |
Average Days of Receivables |
— | 9.56 | 69.88 | 13.18 | 69.27 | 104.71 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 79.23% | 2,559.75% | 1,210.69% | 363.73% | 669.18% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 45.56% | 1,485.49% | 657.43% | 159.24% | 242.46% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 18.19% | 527.70% | 210.50% | 57.77% | 83.30% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | 0.80 | 0.50 | 0.51 | 0.32 | 0.29 | — | — | — |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
— | (4.26%) | (21.91%) | (31.39%) | (12.95%) | (24.00%) | — | — | — |
Free Cash Flow Yield |
— | (0.86%) | (20.69%) | (27.86%) | (12.82%) | (18.52%) | — | — | — |
Revenue per Share |
0.00 | 1.29 | 0.05 | 0.14 | 0.54 | 0.35 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.95) | (0.04) | (1.48) | (2.16) | (2.22) | (2.12) | (3.57) | (17.95) | (28.23) |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.04) | (0.05) | (0.05) | (0.08) | (7.14) | (2.68) |
Free Cash Flow per Share |
(0.95) | (0.04) | (1.49) | (2.20) | (2.27) | (2.17) | (3.65) | (25.09) | (30.92) |
Cash per Share |
5.56 | 3.89 | 3.85 | 4.51 | 6.17 | 4.45 | 8.76 | 57.91 | 0.57 |
Shareholders Equity per Share |
5.51 | 3.92 | 3.84 | 4.42 | 5.98 | 3.75 | 7.89 | 60.46 | 1.86 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.51 | 3.92 | 3.84 | 4.42 | 5.98 | 3.75 | 7.89 | 60.46 | 1.86 |
Free Cash Flow |
(60.38) | (2.50) | (91.47) | (99.01) | (80.19) | (55.00) | (40.34) | (31.54) | (21.98) |
Working Capital |
344.43 | 238.88 | 228.52 | 190.79 | 206.80 | 92.79 | 87.94 | 69.87 | (1.45) |
Capital Expenditures |
(0.31) | (0.28) | (0.51) | (1.96) | (1.71) | (1.34) | (0.85) | (8.98) | (1.91) |
Net Current Asset Value |
340.20 | 232.24 | 219.70 | 179.78 | 202.54 | 85.11 | 76.80 | 64.32 | (1.68) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.18 | 0.31 | 0.09 | 0.15 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.49 | 0.41 | 0.42 | 0.35 | 0.34 | 0.28 | 0.22 | 0.13 | 0.24 |
Cash ROIC |
(8.61%) | (0.52%) | (19.40%) | (24.64%) | (18.66%) | (26.43%) | (21.94%) | (21.20%) | (1,271.37%) |
Accounts Receivable Turnover |
— | 60.77 | 7.32 | 3.28 | 6.21 | 6.68 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 1.32 | 0.38 | 1.93 | 3.08 | 1.32 | 0.31 | 0.27 | 0.27 |
Average Payables |
1.38 | 1.96 | 3.20 | 4.21 | 4.43 | 3.13 | 1.72 | 1.47 | 1.47 |
Average Assets |
313.50 | 259.21 | 242.19 | 230.84 | 182.29 | 120.01 | 98.11 | 45.06 | 45.06 |
Average Common Equity |
296.02 | 239.11 | 217.07 | 205.24 | 153.36 | 91.17 | 11.74 | (48.47) | (48.47) |
Columns are period end dates